Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

November 2nd 2022

Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.

Dr. Johnson on the Effect of the IPSOS Trial on Treatment in Platinum-Ineligible NSCLC

November 2nd 2022

Melissa L. Johnson, MD, discusses the paradigm-shifting results of the phase 3 IPSOS trial of atezolizumab in patients with metastatic non–small cell lung cancer.

Receiving Molecular Testing Results for NSCLC

November 2nd 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

Integrating Molecular Testing Results into Electronic Medical Records

November 2nd 2022

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Lorlatinib Improves PFS, Reduces CNS Progression in Advanced ALK+ NSCLC

November 2nd 2022

Lorlatinib improved progression-free survival and reduced 12-month cumulative incidence of central nervous system progression compared with crizotinib in patients with advanced ALK-positive non–small cell lung cancer irrespective of brain metastases at baseline.

Telisotuzumab Vedotin Plus Erlotinib Shows Encouraging Activity in Advanced c-Met+ NSCLC

November 1st 2022

Telisotuzumab vedotin in combination with erlotinib induced promising outcomes in patients with advanced, EGFR-mutated, c-MET-positive non–small cell lung cancer who were contraindicated for surgery or other approved therapies.

Thoracic Experts Review ESMO 2022 Data in NSCLC

October 31st 2022

In a special OncLive video program, The Board, D. Ross Camidge, MD, PhD, led a discussion regarding key abstracts that were presented during the 2022 ESMO Congress in non–small cell lung cancer.

Sunvozertinib Showcases Early Safety, Efficacy in EGFR Exon 20–Mutated NSCLC

October 30th 2022

D. Ross Camidge, MD, PhD, discusses the potential utility of sunvozertinib in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations, the efficacy and safety data observed with the agent, and future research directions.

NVL-520 Demonstrates Preliminary Clinical Activity in ROS1-Positive NSCLC

October 28th 2022

The novel brain-penetrant ROS1-selective inhibitor NVL-520 elicited clinical activity and was well tolerated in heavily pretreated patients with ROS1 fusion–positive non–small cell lung cancer.

Taletrectinib Shows Promising ORR and Tolerability in ROS1+ NSCLC

October 26th 2022

Misako Nagasaka, MD, PhD, discusses the various needs taletrectinib meets in the ROS1-positive population, initial efficacy data with the agent, and its impressive safety profile.

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

October 26th 2022

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

October 26th 2022

Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.

Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial

October 26th 2022

Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.

The Role of Adjuvant Therapy in Patients with NSCLC

October 26th 2022

Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.

Using Liquid Biopsy for Molecular Testing in NSCLC

October 26th 2022

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLC

October 26th 2022

Julien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non–small cell lung cancer.

Types of Tissue Next-Generation Sequencing Platforms in NSCLC

October 26th 2022

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Sintilimab Plus Chemotherapy Improves PFS in Pretreated, EGFR-Mutant NSCLC

October 25th 2022

Sintilimab plus pemetrexed and cisplatin significantly improved progression-free survival vs pemetrexed and cisplatin alone in patients with advanced, EGFR-mutant non–small cell lung cancer who progressed on prior EGFR TKI therapy.

Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer Diagnosis

October 24th 2022

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

Ivonescimab Gets Breakthrough Therapy Designation in China for EGFR+ Advanced NSCLC

October 21st 2022

The China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab for use in combination with chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in whom prior treatment with an EGFR TKI has failed.